8 minute read
How ‘solution stacking’ can rein in pharmacy benefit costs
An idea that cycles through multiple specialty drug programs and often leads to a major cost reduction.
By Kevin Kobielski
Brokers and employer groups alike know that 5% to 10% of insured workers and their dependents drive 50% to 60% of the cost of pharmacy claims. A few members with prescriptions for a specialty drug with a five-figure price tag can easily represent the majority of an entire group’s pharmacy spend.
These drugs are often lifesaving or provide a dramatic quality of life improvement for those who take them. No one would question the necessity of using them. But when a group can mitigate some of the cost without affecting the clinical outcome, it can be a game changer. The broker who unlocks these savings becomes a trusted ally.
Typically, plan sponsors believe they don’t have many options for specialty drug claims and simply end up paying them. But that’s not the case. When one solution doesn’t work, there are likely several more options to try. A little ingenuity can make a significant impact on drug spend and trends. This is a technique I describe as “solution stacking,” which cycles through multiple specialty drug programs and often leads to a major cost reduction. Here’s how solution stacking works.
Step 1: Select the right pharmacy benefit management partner.
The foundation of this solution is selecting a pharmacy benefit manager that is willing to work with outside solutions. Since the profit margins of most PBMs are inversely tied to the number of programs they allow, this can be a challenge. But there are PBMs out there that highlight their flexibility as a differentiator.
Step 2: Build flexibility into the PBM contract.
Solution stacking is possible only if the PBM allows it. When structuring a PBM contract, make sure it allows the client to bring in third-party solutions. This must be specified in the contract to ensure access to these programs. This includes a commitment from the PBM to support any required data feeds at no cost and stipulates that implementing these programs will not affect pricing terms.
Step 3: Identify the greatest potential savings.
Most drug manufacturers provide incomebased manufacturer assistance programs (MAPs) for high-cost specialty drugs. If the member with a high-cost pharmacy claim qualifies for one of these programs, it typically results in the group paying only about 30% of the cost of the original claim.
Imagine a member — let’s call her Cindy — has a prescription with an annual cost of $100,000. If her income is low enough to qualify for a MAP, the plan sponsor would pay only $30,000, a savings of 70%.
Plan sponsors and members must be proactive about MAPs. These programs aren’t triggered automatically. If the member doesn’t apply and provide income documentation, the plan sponsor is still responsible for the entire cost of the drug.
eligible for a MAP, a good Plan B is typically international mail order. These programs source drugs from other countries with health care systems on par with the U.S., such as Canada and New Zealand. The savings average around 50%, so Cindy’s plan sponsor would be paying $50,000 instead of the full $100,000.
Each international mail-order solution may source from a different country, so it can take more than one attempt to source the drug. For example, only two of the three formulations of Humira are available in Canada. If the member needs that third formulation, an international filling partner sourcing from Canada will come up empty and you’ll have to shop around.
Step 5: Try domestic filling, specialty copay and dosage optimization.
Now, let’s assume that the drug is not available internationally. Plan C is likely going to be sourcing it through another specialty pharmacy outside of your PBM. The savings here are more modest, maybe 20%. But that $20,000 reduction on Cindy’s claims is still significant.
This option is usually paired with a specialty copay program to ensure the group can take advantage of any specialty copay dollars. Specialty copay programs do not require income thresholds, so everyone qualifies.
One factor to consider here is rebates. Although the price could be lower at an outsourced specialty pharmacy, the rebate from the PBM could be higher. It’s also possible that the outsourced specialty pharmacy gets a better rebate as well as a better price.
Outsourcing to another specialty pharmacy can work well in conjunction with dosage optimization, where outreach to the provider ascertains if it might be possible to swap in a generic or switch to a different form of dosage. For example, the prostate cancer drug abiraterone costs $10,000 for 500 mg tablets. But two 250 mg tablets? That’s only $500, decreasing the cost by 95%.
Step 6: Member engagement.
In order to get the most out of the program, there must be tight coordination between the broker, the group and the vendor. Getting members enrolled requires a bit of legwork on their end, so engaging the members early is key to success.
Drug name What it treats
Zokinvy
Myalept
Hutchinson-Gilford progeria syndrome, which causes premature aging Leptin deficiency in people with generalized lipodystrophy Mavenclad Multiple sclerosis
Ravicti Urea cycle disorders
Actimmune
Osteopetrosis and chronic granulomatous disease
Oxervate
Neurotrophic keratitis, which makes the corneas less sensitive
Takhzyro
Juxtapid
Angioedema, a disease that causes swelling underneath the skin
Homozygous familial hypercholesterolemia, which can lead to heart disease
Gattex Short bowel syndrome Chenodal Gallstones
Acthar Gel
Lupus, rheumatoid arthritis, multiple sclerosis, infantile spasms, ophthalmic conditions and psoriatic arthritis Orladeyo Hereditary angioedema
Tegsedi
Nerve damage from hereditary transthyretin amyloidosis Ayvakit Gastrointestinal stromal tumors Qinlock Tumors in the gastrointestinal tract Korlym High levels of cortisol in the body
Vitrakvi
Recorlev
Cancerous tumors with genes that fused together abnormally Endogenous Cushing’s syndrome (lowers the body’s cortisol amount)
Cortrophin Gel
Tibsovo
Rheumatic disorders, collagen diseases and dermatologic diseases Acute myeloid leukemia, cancer of the blood and bone marrow
Monthly cost
(based on length of therapy)
$89,480
$77,496
$63,993 $57,998
$55,310
$50,874
$48,233
$47,897
$42,913 $42,570
$41,459
$38,427
$36,707
$35,213 $35,199 $34,620
$33,784
$32,400
$31,851
$30,083
Worth the effort
It may seem odd to devote so much attention to managing a handful of specific claims. But even a savings of 10% on claims of this size is significant. Most employers spend 50% of their pharmacy costs on a very small amount of specialty users. So this additional work can have a significant return on investment. By exploring multiple solutions, you increase the likelihood that the member and their drug will fit one of those solutions.
Kevin Kobielski, CPA, is president of AlignRx Consulting, a pharmacy benefits consulting firm. Kevin may be contacted at kevin.kobielski@innfeedback.com.
Financial discipline leads to better sleep
Forget the warm milk or white noise. If you really want to get a good night’s sleep, you need a financial advisor. That’s the word from the Northwestern Mutual 2022 Planning & Progress Study, which found that people who work with an advisor say they sleep better and are happier.
Although consumers who work with advisors may be sleeping better, the same cannot be said for the majority of the consumers who took part in the survey. The researchers reported that 54% of adults 18 years and older reported that they are somewhat or very anxious about their finances.
The level of anxiety increases even more for younger adults, with two-
thirds (66%) of both millennials and Generation Z saying they feel some-
what or very anxious about their finances. And a generational breakdown across wellness categories reveals that Gen Xers are the worst sleepers, and millennials and Gen Zers are tied for the most anxious.
Study finds Americans worry about the wrong retirement risks
Americans believe asset volatility is the big scary monster threatening their retirement. But the reality is that there are other monsters just as likely to upset their post-employment lives. The latest study brief from the Center for Retirement Research at Boston College is titled “How Well Do Retirees Assess the Risks They Face in Retirement?” The answer is not very well at all. The risks retirees tend to downplay include longevity,
health, market risk, family issues and Social Security sol-
vency. In addition, Americans largely are unprepared to handle long-term care expenses.
Keep moving forward despite rising rates, advisors say
With the Federal Reserve hiking interest rates, many investors and everyday consumers wonder how they should proceed in a volatile environment. Should they buy that house or get a new car? Or should they wait to see whether interest rates and prices come back down?
Some advisors are telling clients not
to let rising interest rates deter their
plans to buy.
“If you find the home you like or the car you want, you should go forward,” Don Detts Jr., a certified financial planner with Wells Fargo Advisors in Southpointe, Pa., told the Washington (Pa.) ObserverReporter.
Detts and other financial advisors pointed out that even though interest rates on a 30-year, fixed-rate mortgage are now at 5.54%, a little more than double what they were a year ago, rates are still well below what they were 40 years ago, when the Federal Reserve broke the back of inflation with punishing rate hikes. In those days, interest on fixed-rate mortgages could run as high as 13%.
goforit
Americans prepare for economy’s next act
Just as Americans emerge from the COVID-19 pandemic, they are faced with fears of an economic downturn and high inflation. So what are consumers doing about these fears? Prudential found some answers in its most recent Pulse research series.
To prepare for leaner times ahead, Americans are already taking action, cutting back on meals and entertainment outside the home (42%), canceling monthly subscription plans (29%) — including streaming services — and setting aside more money for emergencies (26%).
Americans are increasingly relying on
nontraditional investments like crypto-
currency — which, the survey found, investors owned at levels equal to more traditional investments like mutual funds and exchangetraded funds.
SMASH THAT LIKE BUTTON
30% of Americans say social media is a leading source of financial information and advice.
